Viral Vector Vaccines Market Report and Forecast 2025-2034

The global viral vector vaccines market size was valued at USD 820.22 Million in 2024, driven by the increasing awareness about gene therapy among government and people across the globe. The market size is anticipated to grow at a CAGR of 19.60% during the forecast period of 2025-2034 to achieve a value of USD 4.91 billion by 2034.

Viral Vector Vaccines: Introduction

Viral vector vaccines are a type of vaccine that uses a harmless virus to deliver a piece of genetic material from a pathogen (like a virus or bacterium) into the body. This genetic material instructs cells to produce a specific part of the pathogen, usually a harmless piece called an antigen. The immune system recognizes this antigen as foreign and mounts a protective immune response, producing antibodies and memory cells.

Global Viral Vector Vaccines Market Analysis

The increasing use of gene therapy across a wide range of medical conditions, such as infectious diseases, and others including cancer, genetic disorders, and autoimmune conditions, is a major trend influencing the market growth. Viral vectors are employed in gene therapy to deliver functional genes into cells to treat genetic disorders. The genetic material can correct mutations, replace missing proteins, or modulate gene expression.

The increasing number of license approvals is significantly driving the market growth, including the recent license approval made by the FDA. The FDA has accepted Vertex Pharmaceuticals' biologics license application (BLA) for exagamglogene autotemcel (exa-cel) for treating severe sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). The FDA has granted priority review for SCD with a Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2024, and Standard Review for TDT with a PDUFA target action date of March 30, 2024.

Viral vectors are used in gene therapy to deliver functional genes into cells to treat genetic disorders. The genetic material can correct mutations, replace missing proteins, or modulate gene expression. Increased awareness of viral vector vaccines, driven by high-profile vaccine campaigns, is positively influencing perspective of people about the utilization and benefits of viral vector vaccines, further boosting the global viral vaccines market growth.

Beacon Therapeutics is a leading ophthalmic gene therapy company launched with USD 120 million in June 2024. The investments were made by Syncona Limited and other investors, acquiring assets from a program entitled AGTC at the University of Oxford. The lead asset obtained by Beacon is AGTC-501, an investigational gene therapy intended to treat X-linked retinitis pigmentosa, which is currently being evaluated in multiple clinical trials.

Global Viral Vector Vaccines Market Segmentations

The report titled “Viral Vector Vaccines Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Others

Market Breakup by Applications

• Antisense and RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

Market Breakup by Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

Market Breakup by End User

• Pharmaceutical
• Biopharmaceutical Companies
• Research Institute

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Global Viral Vector Vaccines Market Overview

The rising prevalence of target disease and disorders is continuously driving the market growth. The increasing awareness among people about the importance and application of gene therapy is also driving the market growth. The availability of funding for gene therapy delivery due to the investments by government and key players of the market is also contributing to the viral vector vaccines market growth.

The rising incidence of genetic disorders, cancer, HIV, tuberculosis, cardiovascular diseases, and infectious diseases are driving the market growth. The rising number of clinical trials, increasing investments towards the development of gene therapies, and potential uses for novel drug delivery systems are all collectively driving the market growth. The increasing geriatric population is also a major cause of market growth across the globe. The increasing technological advancements in the production of viral vectors is also an accountable for the global viral vector vaccines market growth. The high operational cost associated with cell and gene therapy manufacturing is expected to restrain the growth of the market.

North America is currently leading the global market due to the presence of highly advanced and equipped research labs to carry research leading to the development of viral vector vaccines. The development of novel medicines is done at a fast pace in the region with the use of viral and non-viral vectors. These vectors can deliver a gene to a specific cell or tissue in vivo. Adeno-associated virus, lentivirus, and retrovirus are examples of viral vectors used in clinical and preclinical trials to evaluate gene and cell therapy products and vaccines.

Viral Vector Vaccines Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novasep
• Merck KGaA
• Charles River Laboratories
• uniQure N.V
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Oxford Biomedical
• Thermo Fisher Scientific Inc

This product will be delivered within 3-5 business days.